EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Engineering Genome‐Free Bacterial Cells for Effective SARS ‐ COV ‐2 Neutralisation

Yutong Yin, Chang Liu, Xianglin Ji, Yun Wang, Juthathip Mongkolsapaya, Gavin R Screaton, Zhanfeng Cui, Wei E Huang iD

Microbial Biotechnology · 2025

DOI: 10.1111/1751-7915.70109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbial Biotechnology, 2025. Verfasst von Yutong Yin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Engineering Science, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: SARS-CoV-2, Escherichia coli, Single-Domain Antibodies, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Engineering and Physical Sciences Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID‐19 pandemic has caused unparalleled impacts on global social dynamics, healthcare systems and economies, highlighting the urgent need for effective interventions to address current challenges and future pandemic preparedness. This study introduces a novel virus neutralisation platform based on SimCells (~1 μm) and mini‐SimCells (100–200 nm), which are chromosome‐free and non‐replicating bacteria from an LPS‐free Escherichia coli strain (ClearColi). SimCells and mini‐SimCells were engineered to display nanobodies on their surface, specifically targeting the receptor‐binding domain (RBD) of the SARS‐CoV‐2 spike protein – a critical immunogenic fragment essential for viral entry into host cells. It was demonstrated that nanobody‐expressing SimCells achieved over 90% blocking efficiency against synthesised RBD from both the original Wuhan and the B.1.351 (Beta) variant using competitive enzyme‐linked immunosorbent assay (ELISA) assay. More importantly, live virus neutralisation assays demonstrated that NB6 nanobody‐presenting mini‐SimCells effectively neutralised the live SARS‐CoV‐2 Victoria variant with an IC50 of 2.95 × 10 9 ± 1.40 × 10 8 mini‐SimCells/mL. Similarly, VE nanobody‐presenting mini‐SimCells effectively neutralised the B.1.351 (Beta) variant of the SARS‐CoV‐2 virus with an IC50 of 5.68 × 10 9 ± 9.94 × 10 8 mini‐SimCells/mL. The mini‐SimCells successfully protected Vero cells, a cell line derived from the kidney of an African green monkey, from infection by the live virus of SARS‐CoV‐2 and its variants. These results suggest that SimCell‐based neutralisation offers a promising strategy for the prevention and treatment of SARS‐CoV‐2, and potentially other viral infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Escherichia coliSingle-Domain AntibodiesCOVID-19Antibodies, NeutralizingSpike Glycoprotein, CoronavirusHumansAnimalsChlorocebus aethiopsVero CellsAntibodies, Viral

Stichwörter der Autor:innen

SimCellbacterial therapychromosome‐freelive virus neutralisationmini‐SimCellsynthetic biologysynthetic cell

Substanzen

Spike Glycoprotein, CoronavirusSingle-Domain Antibodiesspike protein, SARS-CoV-2Antibodies, NeutralizingAntibodies, Viral

Autor:innen und Institutionen

  • Department of Engineering Science, University of Oxford, Oxford, UK.
  • Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.
  • Oxford Suzhou Centre for Advanced Research (OSCAR), University of Oxford, Suzhou Industrial Park, Suzhou, Jiangsu, China.
  • Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand.
  • Department of Medicine, University of Oxford, Oxford, UK.

ORCID-Profile: Wei E Huang

Förderung

  • Engineering and Physical Sciences Research Council

Zitieren

APA

Yin, Y., Liu, C., Ji, X., Wang, Y., Mongkolsapaya, J., Screaton, G. R., Cui, Z., & Huang, W. E. (2025). Engineering Genome‐Free Bacterial Cells for Effective SARS ‐ COV ‐2 Neutralisation. Microbial Biotechnology. https://doi.org/10.1111/1751-7915.70109

Vancouver

Yin Y, Liu C, Ji X, Wang Y, Mongkolsapaya J, Screaton GR, et al. Engineering Genome‐Free Bacterial Cells for Effective SARS ‐ COV ‐2 Neutralisation. Microbial Biotechnology. 2025. doi:10.1111/1751-7915.70109

BibTeX
@article{Yin2025,
  author = {Yin, Yutong and Liu, Chang and Ji, Xianglin and Wang, Yun and Mongkolsapaya, Juthathip and Screaton, Gavin R and Cui, Zhanfeng and Huang, Wei E},
  title = {Engineering Genome‐Free Bacterial Cells for Effective SARS ‐ COV ‐2 Neutralisation},
  journal = {Microbial Biotechnology},
  year = {2025},
  doi = {10.1111/1751-7915.70109}
}
Kostenlos starten →